REFERENCES

1. World Health Organization. Fact sheet 39- All cancers. 2018. Available from https://gco.iarc.fr/today/data/factsheets/cancers/39-All-cancers-fact-sheet.pdf. [Last accessed on 15Feb 2020].

2. Gottesman MM, Pastan I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427.

3. Gottesman MM. Mechanisms of cancer drug resistance. Annu Rev Med 2002;53:615-27.

4. Coley HM. Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer. Cancer Treat Rev 2008;34:378-90.

5. Sharma V, Piwnica-Worms D. Monitoring multidrug resistance P-glycoprotein drug transport activity with single-photon emission computed tomography and positron emission tomography radiopharmaceuticals in: contrast agents IIIRadiopharmaceuticals - from diagnostics to therapeutics. Top Curr Chem 2005:155-78.

6. Mohan HK, Miles KA. Cost-effectiveness of 99mTc-sestamibi in predicting response to chemotherapy in patients with lung cancer: systematic review and meta-analysis. J Nucl Med 2009;50:376-81.

7. Kannan P, John C, Zoghbi SS, Haldin C, Gottesman MM, et al. Imaging the function of P-glycoprotein with radiotracers: pharmacokinetics and in vivo applications. Clin Pharmacol Ther 2009;86:368-77.

8. Mendes F, Paulo A, Santos I. Metalloprobes for functional monitoring of tumor multidrug resistance by nuclear imaging. Dalton Trans 2011;40:5377-93.

9. Piwnica-Worms D, Chiu ML, Budding M, Kronauge JF, Kramer RA, et al. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res 1993;53:977-84.

10. Ballinger JR, Bannerman J, Boxen I, Firby P, Hartman NG, et al. Technetium-99m-tetrofosmin as a substrate for P-glycoprotein: in vitro studies in multidrug-resistant breast tumor cells. J Nucl Med 1996;37:1578-82.

11. Ballinger JR, Muzzammil T, Moore MJ. Technetium-99m-furifosmin as an agent for functional imaging of multidrug resistance in tumors. J Nucl Med 1997;38:1915-9.

12. Rao VV, Herman LW, Kronauge JF, Piwnica-Worms D. A novel areneisonitrile Tc complex inhibits the transport activity of MDR P-glycoprotein. Nucl Med Biol 1998;25:225-32.

13. Bolzati C, Carta D, Gandin V, Marzano C, Morellato N, et al. (99m)Tc(N)-DBODC(5), a potential radiolabeled probe for SPECT of multidrug resistance: in vitro study. J Biol Inor Chem 2013;18:523-38.

14. Chen S, Zhang Y, Li X, Jia H, Lu J. The evaluations of ^99mTc cyclopentadienyl tricarbonyl triphenyl phosphonium cation for multidrug resistance. Bioorg Med Chem Lett 2017;27:3551-4.

15. Schillaci O, Spanu A, Madeddu G. [99mTc]sestamibi and [99mTc]tetrofosmin in oncology: SPET and fusion imaging in lung cancer, malignant lymphomas and brain tumors. Q J Nucl Med Mol Imaging 2005;49:133-44.

16. Wang XS, Zhang YJ, Liu XL, Zhou ZR, Hu CS, et al. The role of technetium-99m methoxyisobutyl isonitrile scintigraphy in predicting the therapeutic effect of chemotherapy against nasopharyngeal carcinoma. Cancer 2011;117:2435-41.

17. Saggiorato E, Angusti T, Rosas R, Martinese M, Finessi M, et al. 99mTc-MIBI Imaging in the presurgical characterization of thyroid follicular neoplasms: relationship to multidrug resistance protein expression. J Nucl Med 2009;50:1785-93.

18. Duan XY, Wang JS, Liu M, Guo YM. Technetium-99m-hexakis-2-methoxyisobutylisonitrile scintigraphy and multidrug resistance-related protein expression in human primary lung cancer. Ann Nucl Med 2008;22:49-55.

19. Mubashar M, Harrington KJ, Chaudhary KS, Lalani E, Stamp GW, et al. 99mTc-sestamibi imaging in the assessment of toremifene as a modulator of multidrug resistance in patients with breast cancer. J Nucl Med 2002;43:519-25.

20. Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients. Cancer 2001;92:232-9.

21. Kurata S, Ushijima K, Kawahara A, Kaida H, Kawano K, et al. Assessment of 99mTc-MIBI SPECT(/CT) to monitor multidrug resistance-related proteins and apoptosis-related proteins in patients with ovarian cancer: a preliminary study. Ann Nucl Med 2015;29:643-9.

22. Gomes CM, Welling M, Que I, Henriquez NV, van der Pluijmet G, et al. Functional imaging of multidrug resistance in an orthotopic model of osteosarcoma using 99mTc-sestamibi. Eur J Nucl Med Mol Imaging 2007;34:1793-803.

23. Rowe SP, Gorin MA, Solnes LB, Ball MW, Choudhary A, et al. Correlation of ^99mTc-sestamibi uptake in renal masses with mitochondrial content and multi-drug resistance pump expression. EJNMMI Res 2017;7:80.

24. Liu S, Kim YS, Zhai S, Shi J, Hou G. Evaluation of (64)Cu(DO3A-xy-TPEP) as a potential PET radiotracer for monitoring tumor multidrug resistance. Bioconjug Chem 2009;20:790-8.

25. Maria L, Cunha S, Videira M, Gano L, Paulo A, et al. Rhenium and technetium tricarbonyl complexes anchored by pyrazole-based tripods: novel lead structures for the design of myocardial imaging agents. Dalton Trans 2007:3010-9.

26. Maria L, Fernandes C, Garcia R, Gano L, Paulo A, et al. Tris(pyrazolyl)methane 99mtc tricarbonyl complexes for myocardial imaging. Dalton Trans 2009:603-6.

27. Mendes F, Gano L, Fernandes C, Paulo A, Santos I. Studies of the myocardial uptake and excretion mechanisms of a novel 99mTc heart perfusion agent. Nucl Med Biol 2011;39:209-13.

28. Goethals LR, Santos I, Caveliers V, Paulo A, De Geeter F, et al. Rapid hepatic clearance of 99mTc-TMEOP: a new candidate for myocardial perfusion imaging. Contrast Media Mol Imaging 2011;6:178-88.

29. Bolzati C, Uccelli L, Boschi A, Malagò E, Duatti A, et al. Synthesis of a novel class of nitrido Tc-99m radiopharmaceuticals with phosphino-thiol ligands showing transient heart uptake. Nucl Med Biol 2000;27:369-74.

30. Modica-Napolitano JS, Aprille JR. Basis for the selective cytotoxicity of rhodamine 123. Cancer Res 1987;47:4361-5.

31. Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, et al. A mitochondria-K⁺ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007;11:37-51.

32. Pancrazio JJ, Tabbara IA, Kim YI. Voltage-activated K⁺ conductance and cell proliferation in small-cell lung cancer. Anticancer Res 1993;13:1231-4.

33. Wonderlin WF, Woodfork KA, Strobl JS. Changes in membrane potential during the progression of MCF-7 human mammary tumor cells through the cell cycle. J Cell Physiol 1995;165:177-85.

34. Reed PW. Ionophores. Methods Enzymol 1979;55:435-54.

35. Hanstein WG. Uncoupling of oxidative phosphorylation. Biochim Biophys Acta 1976;456:129-48.

36. Germano G, Chua T, Kiat H, Areeda JS, Berman DS. A quantitative phantom analysis of artifacts due to hepatic activity in technetium-99m myocardial perfusion SPECT studies. J Nucl Med 1994;35:356-9.

37. Kailasnath P, Sinusas AJ. Technetium-99m-labeled myocardial perfusion agents: are they better than thallium-201? Cardiol Rev 2001;9:160-72.

38. Kapur A, Latus KA, Davies G, Dhawan RT, Eastick S, et al. A comparison of three radionuclide myocardial perfusion tracers in clinical practice: the ROBUST study. Eur J Nucl Med Mol Imaging 2002;29:1608-16.

39. Llaurado JG. The quest for the perfect myocardial perfusion indicator...still a long way to go. J Nucl Med 2001;42:282-4.

40. Parker JA. Cardiac nuclear medicine in monitoring patients with coronary heart disease. Semin Nucl Med 2001;31:223-37.

41. Kim YS, He Z, Hsieh WY, Liu S. Impact of bidentate chelators on lipophilicity, stability, and biodistribution characteristics of cationic 99mTc-nitrido complexes. Bioconjug Chem 2007;18:929-36.